Table 2

Characteristics of case reports reporting digestive symptoms in patients treated with secukinumab or ixekizumab

Reference	Sex age (years)	Time before symptoms (months)	IBD family history	IBD personal history	Treated disease	Previous biotherapy	IBD type	IBD location	Treatment	Alternative drugs
73	M 39	6	No	No	PsO	ND	UC	Rectum and colon	IFX	APR
74	M 42	1.5	No	No	AS, uveitis, HLA B27+	ETA, ADA	UC	Colon	CS, IFX	ND
83	F 51	12	No	No	PsA	ND	CD	Ileum	CS, TOF	ND
	M 55	2	No	No	PsA	ND	UC	Colon	CS	ND
	F 43	53	No	No	AS	ND	CD	Ileum and colon	ADA, CER	ND
	M 44	48	No	No	PsO	ND	CD	ND	ND	ND
75	F 36	2	No	No	AS B27+	ETA, ADA, IFX, TOC, CER, GLM, RTX	CD	Ileum and colon	CS, USK	USK
76	M 27	4	No	No	AS	ETA, ADA	UC	Rectum and sigmoid region	5-ASA, CS, IFX, IFX+AZA	IFX+AZA
77	M 42	0.75	Yes	No	PsA	No	UC	Rectum and colon	CS, GLM	GLM
81	F 49	ND	ND	No	PsO	ND	IBD	Colon	CS, IFX	ND
	M 54	short	ND	No	PsO	ND	IBD	Colon	ADA	ND
	M 28	short	ND	No	PsO	ND	IBD	Ileum	USK	USK
80	F 41	5	No	No	PsO	USK	UC	Rectum and sigmoid region	5-ASA, ADA	ADA
37	F 41	0.25	Yes	No	PsO	ADA, USK	UC	Rectum and sigmoid region	Antibiotics, CYC, IFX+MTX	IFX+MTX
82	F 27	12	No	No	PsO	ADA, ETA	UC	Rectum and sigmoid region	CS, USK	USK
	F 46	5	No	No	AS	ND	IBD	Colon	CS,
	M 33	3	No	No	PsA	anti-TNF	IBD	Colon	ADA, USK	USK
78	F 19	2	No	No	PsO	No	CD	Ileum and colon	CS, USK	USK
78	M 60	0.75	No	No	AS HLA B27+	No	UC	Colon	CS, 5-ASA, IFX	ND
85	M 31	3	No	No	PsO	No	UC	Colon	CS, 5-ASA	IFX
84	M 42	3	Yes	No	PsO	No	CD	Colon	CS, IFX	USK

ADA, adalimumab; APR, Apremilast; AS, ankylosing spondylitis; 5-ASA, mesalazine; AZA, azathioprine; CD, Crohn’s disease; CER, certolizumab; CS, Corticosteroids; CYC, cyclosporine; ETA, etanercept; F, Female; GLM, golimumab; IBD, inflammatory bowel disease; IFX, infliximab; M, male; MTX, methotrexate; N, number; ND, not documented; PsA, psoriatic arthritis; PsO, psoriasis; RTX, rituximab; TNF, tumour necrosis factor ; TOC, tocilizumab; TOF, tofacitinib; UC, ulcerative colitis; USK, ustekinumab.